全文获取类型
收费全文 | 692篇 |
免费 | 26篇 |
国内免费 | 47篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 38篇 |
妇产科学 | 3篇 |
基础医学 | 61篇 |
口腔科学 | 11篇 |
临床医学 | 98篇 |
内科学 | 209篇 |
皮肤病学 | 20篇 |
神经病学 | 23篇 |
特种医学 | 152篇 |
外科学 | 24篇 |
综合类 | 24篇 |
预防医学 | 7篇 |
眼科学 | 5篇 |
药学 | 54篇 |
中国医学 | 3篇 |
肿瘤学 | 31篇 |
出版年
2023年 | 2篇 |
2021年 | 4篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2017年 | 7篇 |
2016年 | 5篇 |
2015年 | 20篇 |
2014年 | 16篇 |
2013年 | 20篇 |
2012年 | 9篇 |
2011年 | 9篇 |
2010年 | 29篇 |
2009年 | 27篇 |
2008年 | 14篇 |
2007年 | 46篇 |
2006年 | 14篇 |
2005年 | 9篇 |
2004年 | 8篇 |
2003年 | 4篇 |
2002年 | 17篇 |
2001年 | 16篇 |
2000年 | 6篇 |
1999年 | 9篇 |
1998年 | 45篇 |
1997年 | 47篇 |
1996年 | 55篇 |
1995年 | 30篇 |
1994年 | 31篇 |
1993年 | 20篇 |
1992年 | 9篇 |
1991年 | 11篇 |
1990年 | 8篇 |
1989年 | 33篇 |
1988年 | 27篇 |
1987年 | 21篇 |
1986年 | 21篇 |
1985年 | 15篇 |
1984年 | 14篇 |
1983年 | 6篇 |
1982年 | 15篇 |
1981年 | 11篇 |
1980年 | 14篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 5篇 |
1976年 | 6篇 |
1975年 | 7篇 |
1931年 | 1篇 |
1925年 | 1篇 |
排序方式: 共有765条查询结果,搜索用时 0 毫秒
761.
Sandmaier BM; Storb R; Santos EB; Krizanac-Bengez L; Lian T; McSweeney PA; Yu C; Schuening FG; Deeg HJ; Graham T 《Blood》1996,87(8):3508-3513
We have studied graft-versus-host disease (GVHD) after transplantation of allogeneic peripheral blood stem cells (PBSC) mobilized by either recombinant canine granulocyte colony-stimulating factor (rcG-CSF) alone or combined with stem cell factor (rcSCF). These studies were prompted by the observation of extremely rapid and sustained engraftment of growth factor-mobilized PBSC in the autologous setting using genetically marked cells and changes in function of T lymphocytes from donors that had undergone mobilization. Specifically, lymphocytes from growth factor-treated donors were hyporesponsive in mixed leukocyte culture and in response to Con A, raising hopes that GVHD in dogs given growth factor mobilized allogenic PBSC might be altered in a beneficial way. Eighteen dogs were given a median of 17.1 x 10(8) PBSC/kg from littermate donors after 920 cGy of total body irradiation without postgrafting immunosuppression. Donors were either genotypically DLA-identical (n = 9) or DLA-haploidentical (n = 9). The median number of colony-forming unit-granulocyte macrophage (CFU-GM) infused was 27 x 10(4)/kg, and the number of CD34+ cells in the transplant was on the order of 4.6 x 10(6)/kg. The dogs received a median of 52.8 x 10(7) CD4 cells/kg and 13.7 X 10(7) CD8 cells/kg. All 18 dogs had prompt hematopoietic engraftment of donor cells as assessed by chimerism studies using variable number tandem repeat, as well as cytogenetic markers. Three of the nine dogs given grafts from DLA- identical littermates had fatal GVHD, five had transient GVHD, and one had no GVHD. All nine DLA-haploidentical recipients of PBSC developed fatal hyperacute GVHD. In conclusion, the expectation about rapid engraftment was fulfilled. However, incidence and severity of acute GVHD after transplantation of mobilized PBSC were not different than previously reported for nonmobilized PBSC or marrow. This model will allow for further studies, including T-cell depletion to minimize GVHD without increasing graft rejection. 相似文献
762.
763.
Storb R; Deeg HJ; Thomas ED; Appelbaum FR; Buckner CD; Cheever MA; Clift RA; Doney KC; Flournoy N; Kennedy MS 《Blood》1985,66(3):698-702
Forty-eight patients with chronic myelocytic leukemia, aged 11 to 47, were treated with high-dose cyclophosphamide and fractionated total body irradiation, followed by infusion of marrow from HLA-identical siblings. They were randomized to receive either methotrexate (MTX) (n = 23) or cyclosporine (CSP) (n = 25) as postgrafting prophylaxis for graft-v-host disease (GVHD). All patients had evidence of sustained hematopoietic engraftment. Seventeen of the 25 patients receiving CSP and 17 of the 23 patients receiving MTX are alive between one and almost four (median, 1.7) years, with an actuarial survival rate at three years of 62% and 66%, respectively (P = .60). Also, with respect to most other parameters studied, the two drugs were identical. The probability of acute GVHD was .42 and .46, respectively (P = .70), that of chronic GVHD, .50 and .63 (P = .44), and that of death from transplant-related causes, .30 and .24 (P = .51). There were no differences in the speed of granulocyte and platelet engraftment (P = .82 and .94, respectively), and the duration of hospitalization was comparable (P = .58). Patients receiving MTX required red cell transfusions for a shorter period of time (P = .02), but had a slightly increased morbidity from early oral mucositis. The leukemia recurrence rates were comparable (P = .60). With the regimens used in this study, we conclude that CSP failed to reduce the incidence of GVHD and improve the survival of patients with chronic myelocytic leukemia when compared to results with standard MTX. 相似文献
764.
Wouter A. Pluijms Walther NKA van Mook Bastiaan HJ Wittekamp Dennis CJJ Bergmans 《Critical care (London, England)》2015,19(1)
Endotracheal intubation is frequently complicated by laryngeal edema, which may present as postextubation stridor or respiratory difficulty or both. Ultimately, postextubation laryngeal edema may result in respiratory failure with subsequent reintubation. Risk factors for postextubation laryngeal edema include female gender, large tube size, and prolonged intubation. Although patients at low risk for postextubation respiratory insufficiency due to laryngeal edema can be identified by the cuff leak test or laryngeal ultrasound, no reliable test for the identification of high-risk patients is currently available. If applied in a timely manner, intravenous or nebulized corticosteroids can prevent postextubation laryngeal edema; however, the inability to identify high-risk patients prevents the targeted pretreatment of these patients. Therefore, the decision to start corticosteroids should be made on an individual basis and on the basis of the outcome of the cuff leak test and additional risk factors. The preferential treatment of postextubation laryngeal edema consists of intravenous or nebulized corticosteroids combined with nebulized epinephrine, although no data on the optimal treatment algorithm are available. In the presence of respiratory failure, reintubation should be performed without delay. Application of noninvasive ventilation or inhalation of a helium/oxygen mixture is not indicated since it does not improve outcome and increases the delay to intubation. 相似文献
765.